Although the platelet was initially viewed only as a bystander in haemostasis, it
is now evident that the platelet is in fact a key mediator of thrombosis as well as
inflammation.
D.L. Bhatt and E.J. Topol[1]
Platelets, the smallest of the human blood cells (3.6 × 0.7 μm), are central players
in processes of hemostasis and thrombosis. In addition, platelets are specialized
cells of the innate immune defense, modulators of the inflammatory response, and involved
in wound healing as well as in hematogenic metastasis. They are released from megakaryocytes
in the bone marrow as anucleated fragments into the circulation. When a vessel wall
is damaged, platelets are recruited from the circulation to the unveiled subendothelial
matrix forming a hemostatic plug to close the leak in the vessel wall. On the other
hand, platelets form a thrombus at sites of ruptured atherosclerotic plaques, and
in this way trigger heart attacks and strokes. The immobilization of platelets at
sites of vascular injury requires specific platelet-vessel wall- (adhesion) and platelet-platelet-interactions
(aggregation). The major agonists and adhesion molecules/receptors that mediate these
interactions are summarized in Table [1].
Table 1 Agonists, Ligands, and Receptors Important for Platelet Function
| Platelet Function |
Agonists, Ligands |
Receptors |
| Initial and firm adhesion |
vWF |
GPIb/V/IX |
|
TSP1 |
GPIb/V/IX, CD36 |
|
Collagen |
α2β1, GPVI, CD36 |
|
Fibrinogen |
αIIbβ3
|
|
Fibronectin |
α5β1
[73]
|
|
Vitronectin |
αvβ3
[77]
|
|
Laminin |
α6β1
[74]
|
|
High shear stress |
GPIb/V/IX |
| Activation and amplification |
Thrombin |
PAR1, PAR4, GPIb/V/IX |
|
ADP |
P2Y1, P2Y12
|
|
TxA2
|
TPα, TPβ |
|
Epinephrine |
α2A
|
|
Serotonin |
5-HT2A |
|
MMP-2, MMP-1[75]
[76]
|
? |
|
Immune complexes |
FcγIIa |
|
Complement factors |
C1q, C3a, C5a receptors |
|
Plasmin |
? |
|
Streptokinase |
? |
| Aggregation/amplification and stabilization |
Fibrin |
Activated αIIbβ3
|
|
vWF |
Activated αIIbβ3, GPIb/V/IX |
|
TSP-1[77]
|
Activated αIIbβ3, CD36,IAP |
|
Fibronectin |
Activated αIIbβ3
|
|
sCD40L |
Activated αIIbβ3
|
|
Gas6 |
Axl[78]
[79]
|
|
SDF-1, TARC, MDC |
CXCR4, CCR4[80]
[81]
[82]
|
| vWF, von Willebrand factor; TSP1, thrombospondin-1; ADP, adenosine diphosphate; TxA2, thromboxane A2; MMP, matrix metalloproteinase; IAP, integrin associated protein; SDF, stromal cell-derived
factor; TARC, thymus and activation-regulated chemokine; MDC, macrophage-derived chemokine. |
MECHANISMS OF PLATELET ACTIVATION
MECHANISMS OF PLATELET ACTIVATION
The adhesion of platelets to the subendothelial matrix is the initial step in primary hemostasis.
Platelets interact with extracellular matrix proteins via specific adhesive glycoproteins
(GP). Binding of biochemical agonists to their receptors, receptor cross-linking,
or changes in the plasma membrane induce a complex cascade of signals, transduced
from the membrane into the cytoplasm, which results in platelet activation (outside-in
signaling).[2] In contrast to resting platelets, which are discoid with homogeneously distributed
granules (Fig. [1]A), activated platelets show a change in the assembly of cytoskeleton proteins resulting
in a shape change with extensive formation of pseudopodia originating from the plasma
membrane.[3] Further, the granules centralize and fuse with the plasma membrane via exocytosis
with secretion of the granule content (Fig. [1]B). Some secretion products, such as adenosine diphosphate (ADP) and serotonin, potentiate
the stimulation of more platelets, which are attracted to the damaged vessel wall.
The activation of platelets is associated with the binding of fibrinogen to its major
receptor GPIIb/IIIa (αIIbβ3-integrin), which is essential for platelet bridging and subsequent aggregation. During secondary hemostasis, the amplification of platelet stimulation leads to
procoagulant activity, thrombin generation, and formation of a stable platelet-fibrin plug with subsequent clot retraction.
Platelet Adhesion
In certain conditions of flow, platelets have to slow down to stop at sites of vascular
damage. The high molecular weight (1-10 MDa) multimeric plasma protein von Willebrand
factor (vWF) associates with the major matrix protein collagen on the surface of the
subendothelium and serves as a substrate for platelet adhesion, predominantly under
high shear. The multiple binding sites of vWF multimers enables first contacts to
the GPIb/V/IX complex on platelets leading to formation of firm bonds and platelet
capture. In contrast to vWF monomers, only dimers and multimers are able to cross-link
and to activate the GPIb/V/IX complex. Conformational changes in the GPIb/V/IX or
vWF molecule are thought to modulate these interactions. Under physiological conditions
it is supposed that binding of vWF to collagen enables binding to GPIb/V/IX.[4] Even point mutations in the vWF or GPIb induced spontaneous ligand binding. The
antibiotic ristocetin or the snake venom ingredient botrocetin are used to induce
vWF-GPIb/V/IX interaction in vitro. The modular glycoprotein thrombospondin-1 (TSP1),
which is also integrated in the subendothelial matrix, has been identified to serve
as an alternative adhesion substrate to vWF via GPIb under high shear conditions.[5] In addition to PSGL1, the GPIb/V/XI complex enables rolling of activated platelets
on the endothelium through endothelial P-selectin.[6]
[7]
Under static or low shear conditions, platelets adhere predominantly to collagen of
the subendothelium. Collagen binds initially to GPIa/IIa, cross-links many of these
integrin molecules, and in this way activates platelets.[8] Patients who lack platelet GPIa/IIa have bleeding problems.[9] Other collagen receptors, such as CD36 and GPVI, play important roles in collagen-induced
signaling.[10]
[11] GPVI, the major signaling receptor, is a member of the immunoglobulin superfamily
and is linked to the Fc receptor γ chain. Its signaling pathway is similar to lymphocyte
signaling.[12] Stimulation of platelets as a result of adhesion leads to spreading, activation
of GPIIb/IIa, enabling binding of soluble fibrinogen, and granule secretion (Fig.
[2]).
Figure 1 Morphology of human platelets. (A) Thin section of discoid resting platelets with
evenly distributed granules. (B) Thin section of stimulated platelets, showing formation
of pseudopodia and centralization of granules. DB, dense body; PP, pseudopodium. Magnification
× 21,000.
Figure 2 Primary hemostasis. (A) Platelets recruited from the circulation to the subendothelium
of a damaged vessel wall adhere to vWF and TSP via GPIb/V/IX under high shear conditions
(h). Collagen serves as adhesive substrate for platelets (via GPIa/IIa and GPVI/Fcγ)
under low shear conditions (1). Receptor clustering through multiple binding sites
of matrix proteins induce activation of GPIIb/IIIa with subsequent binding of fibrinogen
(FG) and platelet spreading. Activated platelets secrete several adhesive proteins,
including TSP, which binds back to the platelet surface. Secreted secondary agonists
(ADP, TxA2 and MMPs) amplify activation and attraction of additional circulating platelets.
(B) REM-preparation of human platelets adhered and spread on immobilized collagen.
(C) Scanning electron microscope preparation of a thrombin-stimulated human platelet
with marked pseudopodia. vWF, von Willebrand factor; TSP, thrombospondin, ADP, adenosine
diphosphate; TxA2, thromboxane A2; MMPs, matrix metalloproteinases.
Platelet Secretion
Activated platelets release several granule components which modulate functions of
interacting platelets and blood and vascular cells. Several secretion products of
immobilized platelets stimulate additional circulating platelets which are recruited
to form aggregates. The dense bodies of platelets contain important secondary agonists
like ADP or serotonin. About 50% of platelet ADP is stored in the dense bodies (storage
pool), which is released after platelet activation but cannot be refilled. In contrast,
the metabolic pool of adenine nucleotides, localized in the cytoplasm but not connected
to the dense bodies, is able to synthesize new ADP but cannot be released.[13] ADP is predicted to be the prominent amplifier of initial platelet activation.[14] There are two important ADP receptors on the platelet surface. The P2Y1-receptor mediates mobilization of Ca2 + and shape change and transient aggregation.[15] The P2Y12-receptor is believed to potentiate platelet secretion and to be involved in sustained
irreversible aggregation.[16] Enzymatic conversion of released ADP to inactive adenosine monophosphate (AMP) by
endothelial ecto-ADPase/CD39 limits platelet activation by ADP.[17] A lack of the second aggregation wave after collagen stimulation characterizes disorders
in ADP-mediated platelet activation.
Serotonin (5-hydroxytryptamine, 5-HT), a well-known strong vasoconstrictor, binds
to the Gq-coupled 5HT2A-receptor and amplifies together with ADP the platelet response.
In addition, serotonin may play a procoagulant role in augmenting the retention of
procoagulant proteins like fibrinogen and thrombospondin (TSP) on the platelet surface.[18] The dense tubular system contains a Ca2 + pool which is mobilized during platelet activation. Ca2 + fluxes are central triggers in platelet activation, platelet attraction, and platelet
aggregation.[19] The α-granules contain large adhesive proteins (vWF, TSP1, vitronectin, fibronectin),
mitogenic factors (PDGF, VEGF, TGFβ), coagulation factors (factors V, VII, XI, XIII),
and protease inhibitors (protein C, PAI-1, TFPI), which are released immediately after
platelet activation. Some of the α-granule proteins are synthesized by megakaryocytes
(TSP1,[20] β-thromboglobulin, platelet factor 4); others are endocytosed from the plasma (immunoglobulins,
fibrinogen, vitronectin). Various glycoproteins, for example, P-selectin (CD62P),
are exclusively localized on the α-granule membrane of resting platelets. Upon secretion
the membrane of the α-granule membrane fuses with the plasma membrane and exposes
CD62P on the platelet surface. P-selectin and other activation-dependent glycoproteins,
including CD40L, mediate platelet binding to neutrophils and monocytes.[21] Leukocytes are able to roll on platelets, which are immobilized on the subendothelium,
in a P-selectin-dependent manner (Fig. [2]).[22]
Platelet Aggregation
The aggregation of platelets is characterized by the accumulation of platelets into
a hemostatic plug (Fig. [3]). The central platelet receptor in this process is the GPIIb/IIIa (αIIbβ3-integrin) linking activated platelets through fibrinogen bridges. A resting platelet
presents ∼40,000 to 50,000 GPIIb/IIIa complexes on its surface. In its nonactive state
this integrin cannot bind soluble ligands like plasma fibrinogen, vWF, TSP, fibronectin,
or vitronectin. Only stimulation of a platelet leads to an increase in GPIIb/IIIa
molecules, via α-granule exocytosis, and to activation of surface-exposed GPIIb/IIIa,
enabling binding of soluble ligands. On the other hand, immobilized fibrinogen on
stimulated platelets serves as an adhesive substrate for resting platelets through
GPIIb/IIIa that leads to amplification of primary aggregation.[23] Interaction between GPIIb/IIIa and its ligand is associated with molecular conformational
changes, resulting in a firm connection. Activation-dependent changes in the conformation
of GPIIb/IIIa can be detected biophysically or by specific antibodies. Ligand binding
to GPIIb/IIIa induces additional conformational changes which lead to phosphorylation
of tyrosines of the cytoplasmatic GPIIIa-chain.[24]
[25] Disulfide changes in the GPIIb/IIIa complex by the surface-associated protein disulfide
isomerase induce high affinity binding sites for fibrinogen.[26] Fibrinogen links discoid platelets during the initial platelet-platelet contact.[27] In high shear environments, as found in arterioles and stenosed arteries, platelet
activation/aggregation can be induced by shear itself. In this case, platelets are
first linked by vWF bridges via the GPIb/V/IX complex. This interaction leads to activation
of GPIIb/IIIa (inside-out signaling) and in turn to stable vWF-mediated platelet aggregates.[28]
Figure 3 Aggregation and secondary hemostasis. (A) Fibrinogen or in high shear environments
vWF bridges platelets through activated GPIIb/IIIa, leading to formation of an unstable
platelet plug. Leukocytes are recruited to aggregated platelets via CD40/CD40L and
PSGL1/CD62P interactions. Increased amounts of thrombin are generated on the platelet
plug, which converts bound fibrinogen to fibrin, leading to plug stabilization and
clot retraction. Microparticles as well as adhesion molecules (sCD62P, sCD40L) are
shed from the platelet surface into the circulation as stimuli for leukocytes, T cells,
and endothelial cells. (B) Scanning electron microscope preparation of a nonretracted
platelet plug, induced by collagen. (C) REM-preparation of a platelet-fibrin clot
with recruited red cell(s). vWF, von Willebrand factor; TSP, thrombospondin.
Low-density lipoproteins (LDL) are supposed to be also a ligand of GPIIb/IIIa and
a modulator of platelet function. Increased levels of LDL are found in the plasma
from patients who discontinued statin treatment and these elevated LDL levels are
associated with platelet hyperactivity. The possible link between LDL and a corresponding
prothrombotic state may explain the increased cardiovascular event rate after statin
discontinuation.[29] In addition, platelets recruit leukocytes and T-cells into the growing plug. Interactions
via P-selectin/PSGL1 or CD40L/CD40 mediate activation of leukocytes which trigger
or limit thrombus growth.[30] Circulating platelet-monocyte aggregates are supposed to play a role in enhancing
formation of atherosclerotic plaques as well as in graft occlusion after peripheral
vascular surgery.[31]
[32] Formation of platelet-leukocyte associates via GPIb on platelets and Mac-1 on leukocytes
may be a cause of the phenomenon of rapid clearance of transferred cooled platelets
with activated clustered GPIb/V/IX complexes.[33]
PROCOAGULANT ACTIVITY-MODEL OF RECEPTOR-MEDIATED THROMBIN GENERATION ON PLATELETS
PROCOAGULANT ACTIVITY-MODEL OF RECEPTOR-MEDIATED THROMBIN GENERATION ON PLATELETS
The formation of a stable platelet plug during secondary hemostasis is characterized
by thrombin-mediated conversion of fibrinogen to fibrin. Thrombin is generated on
surfaces of blood and vascular cells. However, the platelet membrane contains a specific
lipid assembly and receptors with high-affinity binding sites for clotting factors,
a favored preferential and specialized locus to induce and modulate secondary hemostatic
processes.[34]
[35]
The plasma membrane of platelets consists predominantly of phospholipids (∼70%), cholesterol,
and glycolipids. The major phospholipids are phosphatidylcholine (PC), sphingomyelin
(SphM), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol
(PI). They are localized asymmetrically in the plasma membrane, with a concentration
of SphM and PC in the outer leaflet and of PE and acetylated arachidonic acid in the
inner leaflet. Enzymes are distributed in a specific manner in different platelet
membranes. It is postulated that only the plasma membrane contains adenylate cyclase.
In contrast, enzymes responsible for thromboxane A2-synthesis, such as phospholipase
A2, diglycerol lipase, cyclooxygenase (CO), and thromboxane synthase, are restricted
to the intracellular dense tubular membranes.[36] Platelet activation is associated with a flip-flop move of anionic phospholipids,
for example, PS, from the inner to the outer leaflet, leading to an increase of PS
from 2 to 12% of the phospholipid content. The exposure of anionic phospholipids on
the platelet surface can be monitored by labeling of platelets with annexin V, a specific
ligand for amino phospholipids.[37] The exposure of PS on aggregated platelets provides a catalytic surface for procoagulant
processes, enabling thrombin generation at the site of injury.[38] A recently identified alternatively spliced form of human tissue factor (TF) exhibits
procoagulant activity when exposed as soluble molecule to phospholipids, suggesting
that soluble TF contributes to thrombus growth.[39]
In contrast to the classic view of secondary hemostasis, a model of controlled thrombin
generation on the platelet surface may explain many unresolved questions regarding
hemophilia or the molecular mechanism of FVIIa in the clotting process. Small amounts
of thrombin are formed on the surface of a TF presenting cell (fibroblast or activated
monocyte or activated endothelial cell, respectively). These amounts of thrombin are
not able to produce a stable fibrin clot, but are enough to activate platelets. Activated
platelets can then bind coagulation factors and cofactors via Ca2 + and by specific receptors.[40]
[41] Platelet-bound cofactors FV and FVIII are protected against cleavage by activated
protein C.[42] On the surface of the platelet, FXIa binds to its receptor GPIb and activates FIX.
In contrast to FXa, which is readily inhibited by TF pathway inhibitor (TFPI) as soon
as it enters the plasma, FIXa, built on TF/FVIIa presenting cells can in addition
diffuse to the activated platelets. On the platelet surface, the Xase complex and
the prothrombinase complex have optimal conditions.[43]
[44] The concerted actions of coagulation factors yield on the platelet surface in a
burst of thrombin formation, so that a stable fibrin clot can be formed (Fig. [4]).[45]
[46]
Figure 4 Model of receptor-mediated thrombin generation. (A) Small amounts of thrombin formed
on the surface of a tissue factor (TF) presenting cell (fibroblast or activated monocyte
or activated endothelial cell, respectively). These amounts of thrombin are not able
to produce a stable fibrin clot, but are enough to activate platelets. (B) Activated
platelets can then bind coagulation factors and cofactors via Ca2 + and by specific receptors. (C) Platelet-bound cofactors FV and FVIII are protected
against cleavage by activated protein C. (D) On the surface of the platelet FXIa binds
to its receptor GPIb and activates FIX. In contrast to FXa that is readily inhibited
by tissue factor pathway inhibitor (TFPI) as soon as it enters the plasma, FIXa, built
on TF/FVIIa presenting cells can in addition diffuse to the activated platelets. On
the platelet surface the Xase-complex and the prothrombinase-complex have optimal
conditions. (E) The concerted actions of coagulation factors on the platelet surface
lead to a burst of thrombin formation, so that a stable fibrin clot can be formed.
aPC, activated protein C; R, receptor; EPR1, effector cell protease receptor 1, PAR,
protease activated receptor.
MICROVESICLE RELEASE/SHEDDING OF ADHESION MOLECULES
MICROVESICLE RELEASE/SHEDDING OF ADHESION MOLECULES
Strong agonists like collagen in combination with thrombin or complement (C5b-9) induce
shedding of microvesicles from the platelet surface. This “budding” process is due
to Ca2 +-mediated activation of calpain and leads to vesicles containing exclusively intracytoplasmatic
substances.[47]
[48] These vesicles are procoagulant and show similar surface expression of activation-dependent
adhesion molecules (P-selectin, CD40L) as stimulated platelets. Platelet-derived microparticles
are found to be increased in the circulation of patients with sepsis or after cardiopulmonary
bypass and are thought to be associated with thrombotic diseases.[49] Therefore, defects in shedding of platelet-microvesicles is associated with bleeding
disorders. It has been shown that platelet-microvesicles bind to and activate leukocytes
and endothelial cells, bridging leukocytes to each other or leukocytes with endothelial
cells via PSGL1 L-selectin, P-selectin/PSGL1, and CD40L/CD40, respectively.[50] Upon platelet stimulation, surface-expressed CD62P as well as CD40L are further
cleaved in soluble fragments.[51]
[52] sCD62P is known to induce a procoagulant state of monocytes. Platelet-derived sCD40L
is supposed to be a potent stimulus for T-cells, endothelial cells, and platelets
and seems to be necessary for stability of arterial thrombi (Fig. [3]).[53]
[54]
[55]
SIGNAL TRANSDUCTION-STIMULATORY SIGNALING
SIGNAL TRANSDUCTION-STIMULATORY SIGNALING
Stimulatory platelet signaling as a result of receptor ligation and receptor cross-linking
leads to production and release of several intracellular messenger molecules: Ca2 +, products of the phospholipase C (PLC)-mediated phosphoinositol hydrolysis, diacylgycerol,
inosit-1,4,5-triphosphat (IP3), and thromboxane A2 (TxA2). Platelet agonists like ADP, TxA2, epinephrine, serotonin, and thrombin interact with seven specific transmembrane
receptors that are coupled by GTP-binding heterotrimeric G-proteins, initiating several
signaling pathways (Fig. [5]). Signaling through receptors coupled to the Gq-family of G-proteins (PAR1, PAR4,
TxA2-receptor, 5-HT2A-receptor) leads to activation of PLC. PLC catalyzes the hydrolysis
of phosphatidyl inositolbisphosphate (PIP2) to IP3, which induces the mobilization
of Ca2 + from the dense tubula system. An increase in intracellular Ca2 + is associated with a phosphorylation of the myosin-light-chain by myosin-light-chain
kinase, a process that is necessary for shape change. In addition, receptor signaling
through Ga12/13-proteins (PAR1, PAR4), contributes to shape change, too.[56] Granule secretion is one relevant process in response to Ca2 + mobilization, which leads to release of ADP from the dense bodies. ADP binds back
to P2Y12 and amplifies platelet activation.[57] Another activation-enhancing pathway is characterized by the synthesis and release
of TxA2 which results from Ca2 +-dependent mobilization of arachidonic acid by phospholipase A2 and subsequent metabolism
through the CO and TxA2-synthase. Secreted TxA2 in turn rebinds to its Gq-coupled TP-receptors and potentiates stimulatory processes.[58] This pathway is not essential for GPIIb/IIIa activation, secretion, and aggregation.[59] Therefore, blocking this pathway by acetylsalicylic acid (COX-inhibitor), TxA2-receptor inhibitors, or TxA2-synthase inhibitors does not inhibit platelet activation completely. Secreted ADP
activates additional Gi-mediated pathways via its P2Y12-receptor, leading to inhibition of adenylcyclase with subsequent decrease of the
activation blocking messenger cAMP. Pepducins, cell-penetrating peptides, are novel
intracellular inhibitors of signal transduction from receptor to G-proteins.[60] It has been shown that epinephrine signaling through Gq-coupled α2a receptor stimulation
shares the final part of the P2Y12-receptor signaling pathway.[61] This “bypass effect” of epinephrine may possibly explain why thienopyridine drugs
(ticlopidine, clopidogrel), affecting the P2Y12-receptor, are not as successful in antithrombotic therapy of ischemic arterial vascular
diseases as hoped.
Figure 5 G-protein coupled seven-transmembrane receptor signaling in platelets. GTP, guanidine
triphosphate; PKC, protein kinase C; TxA2, thromboxane A2, CO, cyclooxygenase; PI3K, phosphatidylinositol-3 kinase; PIP2, phosphatidylinositolbiphosphate;
IP3, inosit-1,4,5-triphosphate; PLA, phospholipase A; AC, adenylatecyclase; cAMP,
cyclic adenosine monophosphate; ADP, adenosine diphosphate; ATP, adenosine triphosphate;
PGI2, prostaglandin I2, R, receptor; PAR, protease activated receptor.
Signaling via collagen, immunoglobulins and vWF depends on nonreceptor tyrosine kinases.
Platelet stimulation in response to collagen involves signaling by the major collagen
receptors GPIa/IIa and GPVI (Fig. [6]). The signaling via GPVI, which is associated with an Fc-receptor γ chain, is similar
to antigen-receptor-mediated signaling in T and B cells.[62]
[63] Cross-linking of GPVI/FcRγ chain by collagen ligation leads to phosphorylation of
the immunoreceptor tyrosine-based activation motif (ITAM) of the FcRγ chain by the
Src-tyrosine kinases Lyn and Fyn with subsequent binding and activation of the nonreceptor
tyrosine kinase Syk. The participation of Syk and the adapters LAT and SLP76 leads
to activation of phospholipase Cγ2 (PLCγ2). The formation of lipid rafts may be essential
for the integration of the key signaling complexes, leading to PLCγ2 activation.[64] Activation of PLCγ2 results in IP3-synthesis, and the subsequent downstream pathways
are similar to those induced by Gq-coupled receptors. As a consequence GPIIb/IIIa
receptors are activated, enabling binding of soluble ligands, which in turn leads
to activation of Syk (outside-in signaling), contributing to actin polymerization
and platelet spreading.[65] Recently it has been revealed that GPIa/IIa may couple to many of the same intracellular
signaling molecules as GPVI.[66]
[67] Therefore, the roles of GPVI and GPIa/IIa are not as easy to distinguish as originally
thought.
SIGNAL TRANSDUCTION-INHIBITORY SIGNALING
SIGNAL TRANSDUCTION-INHIBITORY SIGNALING
For regulation and limitation of collagen-induced thrombus formation, platelets express
platelet-endothelial cell adhesion molecule-1 (CD31), a member of the inhibitory receptor
family. Cross-linking of CD31 includes phosphorylation of immunoreceptor tyrosine-based
inhibition motifs (ITIMS), inhibiting the actions of ITAMS.[68]
[69]
In the absence of a wound, platelet activation is counteracted by signaling from prostaglandin
I2 (PGI2) and EDRF/nitric oxide (NO), released from endothelial cells. Both platelet inhibitors
induce an intracellular increase of the second messenger cAMP/cGMP by activation of
adenylate cyclase (PGI2) and guanylate cyclase (NO), respectively.[70] High concentrations of cyclic mononucleotides lead to a decrease in IP3 synthesis
and Ca2 + mobilization, resulting in reduction of platelet activation.[71]
[72]
These fascinating little cells called platelets are much more important in hemostasis
than originally thought. We are looking forward to a future that will unravel platelets’
role in other physiologic and pathologic processes such as inflammation, sepsis, asthma,
ischemia reperfusion injury, and host defense.
Figure 6 Nonreceptor tyrosine kinase mediated collagen signaling in platelets. Tyrosine-kinases:
c-Src, Fyn/Lyn; non receptor tyrosine kinases; p72Syk, Syk, adapter molecules: LAT, Grads, SLP76; PLC: phospholipase C; ITAM: immunoreceptor
tyrosine based activation motif.
